RESUMO
Abstract Objectives Evidence suggests that ketamine's influence on brain-derived neurotrophic factor (BDNF) might be involved in its mechanism of rapid antidepressant action. We aimed to evaluate the differential impact of ketamine and esketamine on serum BDNF levels and its association with response patterns in treatment-resistant depression (TRD). Methods Participants (n = 53) are from a randomized, double-blind clinical trial comparing the efficacy of single-dose ketamine (0.5mg/kg, n = 27) and esketamine (0.25mg/kg, n = 26) in TRD. Depression severity was assessed before and 24 hours, 72 hours, and 7 days after the intervention, using the Montgomery-Åsberg Depression Rating Scale (MADRS). Blood samples were collected before infusion, 24 hours, and 7 days afterwards. Results There were no significant changes in BDNF levels at post-infusion evaluation points, and no difference in BDNF levels comparing ketamine and esketamine. Both drugs exhibited similar therapeutic effect. There was no association between BDNF levels and response to treatment or severity of depressive symptoms. Conclusion There was no significant treatment impact on BDNF serum levels - neither with ketamine nor esketamine - despite therapeutic response. These results suggest that ketamine or esketamine intervention for TRD has no impact on BDNF levels measured at 24 hours and 7 days after the infusion. This clinical trial is registered on the Japan Primary Registries Network: UMIN000032355.
RESUMO
Basal cell adenoma is a rare benign salivary gland neoplasm that accounts for 1 to 3 percent of all salivary gland tumors. Most cases occur in major salivary glands and are rare in minor salivary glands. Describe a clinical case of basal cell adenoma. A 76-year-old Caucasian Brazilian woman presents with a slow-growing asymptomatic lesion of the upper lip. Physical examination revealed a nodular lesion 1.1 cm in size. The lesion was firm to palpation and the surrounding mucosa had normal color and appearance, without any ulceration. The tumor was surgically removed by excisional biopsy. Biopsy confirmed basal cell adenoma. A systematic literature review was carried out in PubMed, Lilacs and SciELO databases. The review included all articles published before 1992. Until 1991 no differentiation was made between basal cell adenoma and canalicular adenoma. Both pathologies were classified as monomorphic adenoma. This is the seventh case of upper lip basal cell adenoma reported in the literature between 1992 and 2014. Three of the seven cases reported were from Brazil(AU)
El adenoma de células basales es una neoplasia de la glándula salival raro benigno que representa a 1 a 3 por ciento de todos los tumores de las glándulas salivales. La mayoría de los casos ocurren en las glándulas salivales mayores, siendo poco frecuente en las glándulas salivales menores. El objetivo de este estudio fue describir un caso clínico de adenoma de células basales. Una mujer brasileña de raza caucásica de 76 años de edad, quien se queja de un crecimiento lento y asintomático de una lesión en el labio superior. El examen físico reveló una lesión nodular de 1,1 cm de tamaño. La lesión era firme a la palpación y la mucosa circundante tenía color normal y la apariencia, sin ulceración. El tumor fue extirpado quirúrgicamente mediante una biopsia por escisión. La biopsia confirmó adenoma de células basales. Se realizó una revisión sistemática de la literatura se en las bases de datos PubMed, Lilacs y SciELO. Incluimos en esta revisión todos los artículos publicados antes de 1992. Hasta 1991, no se hizo la diferenciación entre adenoma de células basales y adenoma canalicular. Ambas patologías fueron clasificadas como adenoma monomórfico. Este es el séptimo caso de adenoma de células basales de labio superior reportado en la literatura entre 1992 y 2014. Tres de los siete casos reportados provinieron de Brasil(AU)